Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;181(7):2563-2573.
doi: 10.1007/s00431-022-04458-z. Epub 2022 Apr 11.

Acute phase of Kawasaki disease: a review of national guideline recommendations

Laura Scherler  1 , Nikolaus A Haas  1 , Anja Tengler  1 , Joseph Pattathu  1 , Guido Mandilaras  1 , André Jakob  2
Affiliations
Review

Acute phase of Kawasaki disease: a review of national guideline recommendations

Laura Scherler et al. Eur J Pediatr. 2022 Jul.

Abstract

Key aspects of the medical management of Kawasaki disease (KD) are not yet supported by a high evidence level, thus making room for individual recommendations. We performed a structured comparison of existing international KD guidelines to analyze potential differences in the implementation of evidence-based KD recommendations regarding diagnosis and therapy. To identify country-specific guidelines, we took a multilateral approach including a comprehensive PubMed literature, online research, and directly contacting national pediatric associations. We then ran a structured guidelines' analysis and evaluated the diagnostic and therapeutic differences in the context of evidence-based medicine. In this structured guideline analysis, we identified nine national and one European guidelines. According to them all, the diagnosis of KD still relies on its clinical presentation with no reliable biomarker recommended. First-line treatment consistently involves only intravenous immunoglobulin (IVIG) therapy. Recommendations in terms of acetylsalicylic acid, corticosteroids, and additional therapeutic options vary considerably.

Conclusion: According to all guidelines, KD is diagnosed clinically with some variance in defining incomplete KD and being a non-responder to treatment. First-line treatment consistently includes IVIG. Recommendations for additional therapeutic strategies are more heterogeneous.

What is known: • The diagnosis of KD relies on the clinical presentation, entailing challenges in timely diagnosis. • Other treatment options then IVIG are not supported by a high evidence level, making room for individual recommendations.

What is new: • Definition of incomplete KD and being non-responsive to an initial treatment vary to some extent between the national guidelines. • Only IVIG is consistently proposed throughout all guidelines, further therapeutic recommendations vary between the national recommendations.

Keywords: COVID-19 MISC-C; Coronary artery aneurysm; Kawasaki disease; National guideline.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Research. Recruitment flow chart for national guidelines
See this image and copyright information in PMC

References

    1. Burns JCM. Commentary: Translation of Dr. Tomisaku Kawasaki's original report of fifty patients in 1967. Pediatr Infect Dis J. 2002;21(11):993–995. doi: 10.1097/00006454-200211000-00002. - DOI - PubMed
    1. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63(2):175–179. doi: 10.1542/peds.63.2.175. - DOI - PubMed
    1. Ishii M, Ebato T, Kato H. History and future of treatment for acute stage Kawasaki disease. Korean Circ J. 2020;50(2):112–119. doi: 10.4070/kcj.2019.0290. - DOI - PMC - PubMed
    1. Baumer JH, Love S, Gupta A, Haines L, Maconochie IK, Dua JS (2006) Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev (4) - PMC - PubMed
    1. Furusho K, Sato K, Soeda T, Matsumoto H, Okabe T, Hirota T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet (London, England) 1983;2(8363):1359. doi: 10.1016/S0140-6736(83)91109-1. - DOI - PubMed

MeSH terms